Castle Biosciences Inc Quick Ratio (CSTL) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Castle Biosciences Inc   (NASDAQ: CSTL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Castle Biosciences Inc 's Quick Ratio

CSTL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.11 below Castle Biosciences Inc average.

Within Medical Laboratories industry 11 other companies have achieved higher Quick Ratio than Castle Biosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 670 to 840.

Explain Quick Ratio?
How much Cash & cash equivalents CSTL´s has?
What are CSTL´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CSTL/financial-strength
https://api.csimarket.com/api/v1/companies/CSTL/fundamentals
https://api.csimarket.com/api/v1/companies/CSTL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
CSTL Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 22.25 %
Y / Y Cash & cash equivalent Change -3.43 %
Quick Ratio MRQ 4.11
CSTL's Total Ranking # 840
Seq. Current Liabilities Change 19.65 %
Seq. Cash & cash equivalent Change 4.07 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Laboratories Industry # 12
Healthcare Sector # 318
Overall Market # 840


Quick Ratio Statistics
High Average Low
23.15 8.3 0.74
(Mar 31 2021)   (Dec 31 2018)




Financial Statements
Castle Biosciences Inc 's Current Liabilities $ 68 Millions Visit CSTL's Balance sheet
Castle Biosciences Inc 's Cash & cash equivalent $ 278 Millions Visit CSTL's Balance sheet
Source of CSTL's Sales Visit CSTL's Sales by Geography


Cumulative Castle Biosciences Inc 's Quick Ratio

CSTL's Quick Ratio for the trailling 12 Months

CSTL Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 25.25 %
Y / Y Cash & cash equivalent TTM Growth -2.31 %
Quick Ratio TTM 4.58
Total Ranking TTM # 3888
Seq. Current Liabilities TTM Growth 5.37 %
Seq. Cash & cash equivalent TTM Growth -0.89 %


On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $67.61 millions, cumulative Quick Ratio decreased to 4.58 below the Castle Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 33 other companies have achieved higher Quick Ratio than Castle Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3644 to 3888.

Explain Quick Ratio?
How much Cash & cash equivalents CSTL´s has?
What are CSTL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 34
Healthcare Sector # 886
Within the Market # 3888


trailing twelve months Quick Ratio Statistics
High Average Low
19.82 6.41 1.43
(Sep 30 2021)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Billiontoone Inc   9.26 $ 561.512  Millions$ 60.637  Millions
Absci Corp  8.70 $ 173.729  Millions$ 19.958  Millions
Maxcyte inc   6.36 $ 101.280  Millions$ 15.916  Millions
Personalis Inc   5.17 $ 254.841  Millions$ 49.274  Millions
Veracyte Inc   4.40 $ 370.532  Millions$ 84.209  Millions
Castle Biosciences Inc   4.11 $ 277.665  Millions$ 67.612  Millions
Fulgent Genetics Inc   4.07 $ 292.739  Millions$ 71.877  Millions
Omniab Inc   3.81 $ 64.210  Millions$ 16.853  Millions
Guardant Health Inc   2.75 $ 1,026.848  Millions$ 373.165  Millions
Incyte Corporation  2.68 $ 3,854.572  Millions$ 1,437.818  Millions
Exagen Inc   2.14 $ 28.092  Millions$ 13.100  Millions
Biodesix Inc   1.99 $ 28.409  Millions$ 14.248  Millions
Caredx Inc   1.80 $ 250.480  Millions$ 138.975  Millions
Butterfly Network Inc   1.80 $ 122.301  Millions$ 67.987  Millions
Sera Prognostics Inc   1.80 $ 44.089  Millions$ 24.527  Millions
Radnet Inc   1.11 $ 797.880  Millions$ 716.642  Millions
Bioaffinity Technologies Inc   1.01 $ 2.550  Millions$ 2.533  Millions

Date modified: 2026-11-07T13:20:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.